PET scans may improve chemo decisions for abdominal cancer patients

NCT ID NCT06144853

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see if the scans could detect metabolic changes in tumors after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FDG-PET/CT scan

What this could lead to

If successful, this could show that PET scans are a useful tool to guide treatment decisions for people with abdominal cancer spread.

What could go wrong

This is a very small pilot study with only 34 participants, so results may not apply to everyone. It focuses on imaging, not on improving survival or symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer digestive system cancer gastric cancer malignant pancreatic neoplasm ovarian cancer peritoneal carcinomatosis peritoneal neoplasm peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Odense PIPAC Center

    Odense, Funen, 5000, Denmark